布地奈德联合沙丁胺醇雾化吸入治疗慢性阻塞性肺疾病急性加重期的临床疗效观察

    The clinical effects of budesonide combined with salbutamol atomization inhalation on treatment of chronic obstructive pulmonary disease at acute exacerbation phase

    • 摘要: 目的:观察布地奈德联合沙丁胺醇联合雾化吸入对慢性阻塞性肺疾病急性加重期(AECOPD)的临床疗效。方法:100例AECOPD患者随机分为对照组50例, 给予地塞米松10 mg静脉滴注;观察组50例给予布地奈德1 mg和沙丁胺醇溶液0. 5 ml雾化吸入, 每天2次;分别在入院时、治疗第7天、出院前1天观察临床症状评分、血糖、电解质、肺功能、血气分析、合并症及药物不良反应。结果:2组患者治疗后临床症状评分均明显降低, 第1秒用力呼气容积和PaO2、PaCO2均有改善, 2组差异均有统计学意义(P0. 05~P0. 01)。结论:布地奈德和沙丁胺醇联合雾化吸入能够改善AECOPD患者肺功能及临床症状, 优于全身使用糖皮质激素, 且不良反应明显减少。

       

      Abstract: Objective: To observe the clinical effect of budesonide combined with salbutamol atomization inhalation on acute exacerbation phase of chronic obstructive pulmonary disease(AECOPD) . Methods: One hundred patients with AECOPD were randomly divided into two groups:50 patients in control group were injected with dexamethasone(10 mg) intravenously once a day; 50 patients in observed group were treated with budesonide(1 mg) combined with salbutamol(0. 5 ml) atomization inhalation twice a day. The changes of clinical symptom scores, electrolytes levels, blood glucose levels, lung function, blood gas analysis including forced expiratoy volume in the first second, PaO2 and PaCO2 on the first day of 7th day of treatment and the last day before discharge were recorded, meanwhile the side effects were observed. Results: FEV1, PaO2 and PaCO2 in these two groups were improved, and there was significant difference after treatment(P < 0. 05-P < 0. 01) ; the side effect in observed group was significantly less than that in control group. Conclusions: The treatment of budesonide combined with salbutamol atomization inhalation can improve lung function and clinical symptom of patients with AECOPD, which is superior to the effect of intravenous glucocorticoid, and the adverse effect has decreased.

       

    /

    返回文章
    返回